Dyne Therapeutics, Inc.
Dyne Therapeutics, Inc. (DYN) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
dyn · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Dyne Therapeutics, Inc. (DYN) measures how much investors pay for each dollar of the company's trailing earnings. DYN's current PE ratio of N/A is calculated by dividing its stock price of $16.68 by its TTM earnings per share of -$2.74.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2007 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
Historical PE Range
Past 5 fiscal years · Front-end computedMinQ1 · 25%59.7x
MedianQ3 · 75%119.5x
Max
At N/A, DYN's current P/E is lower than in 0% of its annual fiscal year readings over the past 5 years — historically low.
Percentile calculated from annual fiscal year data points, not by trading day. Years where PE ≤ 0 or > 9,999 are excluded.
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Dyne Therapeutics, Inc.You DYN | $2.8B | N/A | — | -$2.74 |
 Ascentage Pharma Group International AAPG | $1.6B | N/A | — | -$13.58 |
 Apogee Therapeutics, Inc. APGE | $5.2B | N/A | — | -$4.22 |
 Celcuity Inc. CELC | $4.2B | N/A | — | -$3.37 |
 CG Oncology, Inc. Common stock CGON | $4.8B | N/A | — | -$2.08 |
 Centessa Pharmaceuticals plc CNTA | $6.1B | N/A | — | -$1.46 |
 Mirum Pharmaceuticals, Inc. MIRM | $4.7B | N/A | — | -$0.47 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | — | $-3.47 | — | |
2024-12-31 FY2024 | — | $-3.37 | — | |
2023-12-31 FY2023 | — | $-3.95 | — | |
2022-12-31 FY2022 | — | $-3.23 | — | |
2021-12-31 FY2021 | — | $-2.93 | — | |
2020-12-31 FY2020 | — | $-1.24 | — | |
2019-12-31 FY2019 | — | $-0.30 | — | |
2018-12-31 FY2018 | — | $-0.47 | — | |
2017-12-31 FY2017 | 50.94x | $0.47 | — | |
2016-12-31 FY2016 | — | $-9.61 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Dyne Therapeutics, Inc. (DYN) measures how much investors pay for each dollar of the company's trailing earnings. DYN's current PE ratio of N/A is calculated by dividing its stock price of $16.68 by its TTM earnings per share of -$2.74.
Frequently asked questions
DYN pe ratio · 6 questionsDYN's current PE ratio is N/A as of 2026-06-08, based on a stock price of $16.68 and TTM EPS of -$2.74. Data sourced from Financial Modeling Prep via DYN's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Dyne Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08